Quote this publication Share Print


Opinions on drugs - Posted on Mar 19 2013

Reason for request

Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.


Actual benefit


The actual benefit of CAPRELSA is substantial.

Improvement in actual benefit

IV (mineur)

The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

Contact Us

Évaluation des médicaments

See also